Μany investors appreciate the
pharmaceutical industry for its potential to produce both income and long-term
growth. Several of the large-cap drug makers offer above-average yields, and
have records of growing their business and payouts over the long term.
Additionally, historically,
many drug markers have acted resiliently during economic downturns and
recessions. These companies are often considered defensive stocks. Many believe
that this industry currently represents a strong long-term value, as several of
these companies will continue to pay substantial dividends, benefit from
emerging market growth, continue to develop new medical advancements and
provide products that are so needed as to ensure continued demand even in the
face of price increases due to inflation. These characteristics make many
investors label this industry as recession proof (or at least recession
resistant).
Below are several large-cap
(over a $10 billion valuation) drug manufacturers that trade within on U.S.
exchanges and that have at least a 4% current yield. I have provided their
present yield, as well as their 1-month, 6-month, 1-year and 5-year share
performance rates.
- AstraZeneca / Yield: 5.97%
- GlaxoSmithKline / Yield: 4.8%
- Eli Lilly / Yield: 4.8%
- Merck / Yield: 4.6%
- Novartis / Yield: 4.27%
- Sanofi / Yield: 5.24%
These large-cap pharmaceutical
makers have acted reasonably well during this volatile last year. Investors who
selected these equities as conservative, value-driven and/or income oriented
stock are broadly happy with their performance, though capricious price
valuations have caused significant fluctuations within this traditionally
low-beta group.
Additionally, though many of
these companies appreciated considerably over the last year, about half have
not recently raised their dividends, or only did so after earlier slashing them
to a greater extent within the last five years. As a result, it appears likely
that several of these companies may institute increases in the coming quarters.
Nonetheless, this group already provides an income investor a yield above the
market average or even a 30-year treasury, with far greater prospects of
capital appreciation.
Φαρμακευτικο Μαρκετινγκ: Θεωρια, Πρακτικη, Δεοντολογια
The ultimate guide for Pharma Marketing
Champions
Ζητήστε
το στα κεντρικά βιβλιοπωλεία ή δώστε την παραγγελία σας τώρα…